Search
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345].
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic IndexOpaganib
go.drugbank.com/drugs/DB12764InvestigationalOpaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.
Amoxapine
go.drugbank.com/drugs/DB00543ApprovedThe antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … See toxicity section below for a complete listing of side effects.
Categories: Dopamine D2 Receptor Antagonists, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexPhentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. … While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalthe accompanying vial of AS01E adjuvant as the adjuvant suspension component. … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalHowever, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008. … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
Pentamidine
go.drugbank.com/drugs/DB00738ApprovedInvestigationalAntiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other t...
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalIt is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. … Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline).
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedSimoctocog alfa is a glycoprotein consisting of 1440 amino acids with an approximate molecular mass of 170 kDa, comprising the FVIII domains A1-A2 + A3-C1-C2 whereas the B-domain, present in the full-length … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.